UCB just made one of the most striking moves in pharma TV ad spending this year. Bimzelx jumped from roughly $5.5 million in estimated national linear TV spending in July to $31.2 million in August, according to iSpot.TV data reported by Fierce Pharma. That surge pushed the immunology brand up 17 positions and into the number one spot. But UCB is not simply buying more commercials. It is buying something harder to build quickly: attention, familiarity, and a stronger place in consumers’ minds within an intensely competitive immunology category.
Table of Contents
- Why Bimzelx’s surge in TV ad spending matters
- UCB is buying share of voice
- Multiple indications make the media economics more interesting
- Why $31 million on TV can still make strategic sense
- Conclusion
- FAQs
Why Bimzelx’s Surge in TV Ad Spending Matters
The size of the increase makes Bimzelx stand out. Estimated spending rose from $5.5 million in July to $31.2 million in August, putting the brand just ahead of AbbVie’s Skyrizi at $30.3 million. Johnson & Johnson’s Tremfya followed at $25.6 million, while AbbVie’s Rinvoq reached $25.3 million. Fierce Pharma reported the rankings using iSpot.TV data.
Therefore, UCB did not enter a quiet advertising market. It pushed Bimzelx directly into one of pharma’s most expensive and competitive media battles.
The allocation also tells an important story. About $11.8 million supported hidradenitis suppurativa messaging, $10.8 million went toward psoriasis, and $8.7 million supported psoriatic arthritis. Eleven different Bimzelx spots ran across those indications.
That breadth matters because Bimzelx is no longer a single-indication story. In the United States, the drug is approved for several inflammatory conditions, including plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. UCB’s prescribing information provides details on its approved uses.
As a result, UCB can use one master brand across several patient populations while building broader familiarity with the Bimzelx name.
UCB Is Buying Share of Voice Before It Buys Action
A television impression has value, but repeated exposure can deliver something more important. It can make a brand easier to remember when a consumer later encounters the disease, searches for treatment information, or speaks with a healthcare professional.
That appears particularly important in immunology. Skyrizi, Tremfya, Rinvoq, Dupixent, and Bimzelx compete for attention in overlapping categories. Consequently, simply appearing on television may not be enough. A brand needs enough weight to become recognizable amid competitors with years of consumer advertising behind them.
Bimzelx’s aggressive TV investment gives UCB a faster route toward that recognition. Instead of slowly accumulating awareness, the company can compress months of exposure into a concentrated media push.
The placement strategy reinforces that point. NFL Network accounted for more than 35% of Bimzelx’s network spend share of voice, while NFL football represented roughly 32.5% of program spend share of voice, according to the iSpot.TV figures reported by Fierce Pharma.
In other words, UCB appears to be buying reach around programming capable of delivering large audiences quickly. That strategy can help make an unfamiliar drug name feel considerably less unfamiliar after only a few weeks.
For pharma marketers, this is a useful reminder that TV advertising does not operate in isolation. The commercial may create awareness, while search, social media, patient websites, HCP communication, and other digital touchpoints carry consumers further through the journey.
Multiple Indications Make the Media Economics More Interesting
The economics become even more compelling when one brand can support several indications.
UCB has rapidly expanded the Bimzelx opportunity. Moreover, the company said in 2025 that the drug had gained five new FDA-approved indications in just over a year. That expansion gave UCB access to a much wider range of people living with chronic inflammatory diseases.
However, wider indications create a communication challenge. A psoriasis patient does not necessarily identify with a hidradenitis suppurativa story. Likewise, someone living with psoriatic arthritis may respond to a different set of symptoms and daily-life situations.
UCB’s answer appears to be creative volume rather than one universal commercial. Five of the August spots focused on psoriatic arthritis, four on psoriasis, and two on hidradenitis suppurativa.
Therefore, the campaign can build the same brand while giving different audiences more relevant entry points.
That is potentially a powerful media advantage. Each indication-specific commercial can reinforce the Bimzelx name even when the individual viewer is not part of that spot’s primary audience.
Meanwhile, the wider campaign builds a sense that Bimzelx is becoming a major immunology franchise rather than simply another new treatment. UCB is effectively using media scale to amplify portfolio scale.
Why $31 Million on TV Can Still Make Strategic Sense
Pharmaceutical TV advertising faces plenty of questions. Consumer viewing habits continue to fragment, digital channels offer stronger targeting, and the regulatory environment around prescription drug promotion remains under scrutiny.
Yet Bimzelx demonstrates why large brands may still see television as valuable.
TV can create reach at a speed that many highly targeted channels cannot easily match. More importantly, it can provide a common starting point for an omnichannel campaign.
A patient sees a Bimzelx commercial during football. Later, that person searches the brand, visits a condition page, watches another video, encounters a paid search result, or asks a physician about treatment options. In that journey, television does not need to complete the conversion by itself.
Instead, it starts the recognition process.
That distinction is essential when evaluating the return on pharmaceutical TV advertising. Measuring the campaign only by immediate response can undervalue the role of broad-reach media. Brand search lift, website visits, patient engagement, HCP conversations, and downstream treatment inquiries can provide a fuller picture.
At the same time, marketers should not assume that spending automatically produces durable awareness. Creative quality, frequency, audience selection, and coordination with digital channels still matter.
The real test will be whether UCB can turn August’s enormous visibility spike into sustained mental availability after the spending surge ends.
Conclusion
Bimzelx’s $31.2 million August push tells a bigger story than the spending figure alone suggests. It shows how UCB is trying to accelerate the development of a multi-indication immunology brand in a market dominated by established competitors.
The company is buying reach, but it is also buying share of voice. Furthermore, it is using indication-specific creative to build one recognizable brand across several patient populations.
The bigger lesson for pharma marketers is simple. Television may no longer own the entire patient journey, but it can still create the first spark of recognition at enormous scale.
If UCB’s strategy works, the most valuable thing purchased with that $31 million will not be the impressions themselves. It will be the moment when a patient hears “Bimzelx” and realizes they already know the name.
FAQs
How much did UCB spend advertising Bimzelx on TV in August 2026?
Estimated national linear TV spending reached about $31.2 million in August, compared with roughly $5.5 million in July, according to iSpot.TV data reported by Fierce Pharma.
Was Bimzelx the biggest pharma TV advertiser in August?
Yes. Bimzelx ranked first in estimated August national linear TV spending, narrowly ahead of AbbVie’s Skyrizi at approximately $30.3 million.
Why is UCB spending so heavily on Bimzelx advertising?
The campaign can build awareness across several inflammatory disease markets while helping Bimzelx compete for consumer attention against established immunology brands such as Skyrizi, Tremfya, Rinvoq, and Dupixent.
Which conditions were featured in Bimzelx TV advertising?
August spending included campaigns focused on hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis. Bimzelx also has additional FDA-approved indications.
Does spending more on pharma TV advertising lead to more prescriptions?
No. Television can build reach and awareness, but prescription decisions involve many additional factors, including clinical appropriateness, physician recommendations, insurance coverage, patient preferences, and the effectiveness of other marketing and educational touchpoints.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
